RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Seres Therapeutics - Stock

Seres Therapeutics EBIT 2024

Seres Therapeutics EBIT

-162.91 M USD

Seres Therapeutics Dividend yield

Ticker

MCRB

ISIN

US81750R1023

WKN

A14VXX

In 2024, Seres Therapeutics's EBIT was -162.91 M USD, a 50.86% increase from the -107.98 M USD EBIT recorded in the previous year.

The Seres Therapeutics EBIT history

YEAREBIT (undefined USD)
2028e206.04
2027e-29.69
2026e-3.51
2025e-143.29
2024e-162.91
2023-107.98
2022-246.5
2021-64.5
2020-88.1
2019-70.4
2018-100.3
2017-91.4
2016-92.8
2015-54.9
2014-15.1
2013-6.1
2012-3

Seres Therapeutics Aktienanalyse

What does Seres Therapeutics do?

Seres Therapeutics Inc is a company specializing in the development of microbiome therapeutics. The company was founded in 2010 by a group of scientists from Harvard University who recognized the potential of the microbiome and were excited by the fact that it has a multitude of impacts on human health. Seres Therapeutics' headquarters are located in Cambridge, Massachusetts, USA. The business model of Seres Therapeutics is based on the research, development, and commercialization of therapeutics based on the microbiome. The microbiome is the collection of all microorganisms, including bacteria, viruses, and fungi, that live in the human body. Seres Therapeutics firmly believes that the microbiome plays a crucial role in maintaining health and aims to develop innovative therapies that can improve the immune system and strengthen the body's defenses based on this. Seres Therapeutics' products are designed for the treatment of gastrointestinal tract diseases, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The company's products harness the potential of the microbiome to improve gut health, particularly by restoring the natural balance of gut flora. In 2016, Seres Therapeutics launched its first approved drug on the market - SER-109, a treatment for recurrent Clostridium difficile infections (CDI). CDI is an infectious disease caused by the bacterium Clostridium difficile and is commonly associated with antibiotic therapies. SER-109 has proven effective in reducing the frequency of CDI infections, making it the first approved microbiome-based therapeutic. Seres Therapeutics is also working on the development of other products. The company has conducted several Phase 2 clinical trials demonstrating the efficacy of its preparations for the treatment of inflammatory bowel disease. Other products in Seres Therapeutics' pipeline are currently being tested for their effectiveness in combating cancer and autoimmune diseases, where the microbiome also plays an important role. Seres Therapeutics is also working to expand its business into other markets. The company has entered into partnerships with leading pharmaceutical companies such as Nestlé and AstraZeneca to explore the potential of microbiome therapy in various indications. Another important initiative of Seres Therapeutics is the exploration of the use of artificial intelligence to identify new microbiome-based therapeutics and improve drug development. Overall, Seres Therapeutics Inc has written a fascinating story by recognizing the potential of the microbiome in combating diseases. The company is on track to become a leading provider of microbiome-based therapeutics and continues its efforts to provide innovative solutions to future medical challenges. Seres Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Seres Therapeutics's EBIT

Seres Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Seres Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Seres Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Seres Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Seres Therapeutics Stock

How much did Seres Therapeutics achieve in EBIT for the current year?

In the current year, Seres Therapeutics has achieved an EBIT of -162.91 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Seres Therapeutics.

How has the EBIT of Seres Therapeutics developed in recent years?

The EBIT of Seres Therapeutics has increased by 50.863% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Seres Therapeutics?

The EBIT of Seres Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Seres Therapeutics pay?

Over the past 12 months, Seres Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Seres Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Seres Therapeutics?

The current dividend yield of Seres Therapeutics is .

When does Seres Therapeutics pay dividends?

Seres Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Seres Therapeutics?

Seres Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Seres Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Seres Therapeutics located?

Seres Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Seres Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Seres Therapeutics from 6/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/9/2024.

When did Seres Therapeutics pay the last dividend?

The last dividend was paid out on 6/9/2024.

What was the dividend of Seres Therapeutics in the year 2023?

In the year 2023, Seres Therapeutics distributed 0 USD as dividends.

In which currency does Seres Therapeutics pay out the dividend?

The dividends of Seres Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Seres Therapeutics

Our stock analysis for Seres Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Seres Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.